1489 studies found for:    "Melanoma"
Show Display Options
Rank Status Study
21 Completed Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Drug: temozolomide;   Drug: thalidomide
22 Completed Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Intervention: Drug: pyrazoloacridine
23 Active, not recruiting Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: IFA;   Biological: 6MHP;   Biological: GM-CSF
24 Active, not recruiting Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: multi-epitope melanoma peptide vaccine;   Biological: sargramostim
25 Completed Study of Temzolomide and Gleevec in Advanced Melanoma
Conditions: Melanoma;   Advanced Melanoma
Intervention: Drug: Gleevec + Temozolomide
26 Completed PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: PEG-interferon alfa-2b;   Drug: thalidomide
27 Completed Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Drug: lomustine;   Drug: temozolomide;   Drug: thalidomide
28 Completed Vaccine Therapy in Treating Patients With Metastatic Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: MART-1 antigen;   Biological: gp100:209-217(210M) peptide vaccine;   Biological: therapeutic autologous dendritic cells;   Biological: tyrosinase peptide
29 Terminated Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: MART-1 antigen;   Biological: gp100 antigen;   Biological: incomplete Freund's adjuvant;   Biological: progenipoietin;   Biological: tyrosinase peptide
30 Completed Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: pegylated interferon alfa;   Drug: temozolomide
31 Completed Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: gp100 antigen;   Biological: incomplete Freund's adjuvant;   Biological: ipilimumab
32 Withdrawn Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
Conditions: Melanoma;   Malignant Melanoma
Interventions: Drug: lovastatin;   Drug: interferon alfa-2b
33 Completed Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Intervention: Biological: mouse gp100 plasmid DNA vaccine
34 Recruiting Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: Axitinib
35 Not yet recruiting Efficacy of Propranolol Treatment to Prevent Melanoma Progression
Conditions: Stages III Skin Melanoma;   Stages II Skin Melanoma;   Stage IB Skin Melanoma
Interventions: Drug: Propranolol hydrochloride;   Drug: Placebo pill
36 Completed Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: MART-1 antigen;   Biological: gp100 antigen;   Biological: incomplete Freund's adjuvant;   Biological: recombinant interleukin-12;   Biological: sargramostim;   Biological: tyrosinase peptide;   Drug: alum adjuvant;   Procedure: adjuvant therapy
37 Completed Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: ipilimumab;   Biological: Tyrosinase/gp100/MART-1 Peptides
38 Completed Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: MART-1 antigen;   Biological: gp100 antigen;   Biological: incomplete Freund's adjuvant;   Biological: ipilimumab;   Biological: tyrosinase peptide;   Procedure: adjuvant therapy
39 Completed Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Conditions: Intraocular Melanoma;   Malignant Conjunctival Neoplasm;   Melanoma (Skin)
Interventions: Biological: MART-1:27-35 peptide vaccine;   Biological: gp100:209-217(210M) peptide vaccine;   Biological: incomplete Freund's adjuvant;   Biological: sargramostim;   Biological: tyrosinase peptide;   Drug: agatolimod sodium;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunologic technique
40 Completed Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: gp100 antigen;   Biological: incomplete Freund's adjuvant;   Biological: recombinant interleukin-12;   Biological: tyrosinase peptide

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years